What Has Been the Growth Trajectory for the Autologous Cell Therapy Market in Recent Years?
The autologous cell therapy market has seen considerable growth due to a variety of factors.
•The market size for autologous cell therapy has significantly expanded in the past few years. It is projected to surge from $10.28 billion in 2024 to $12.19 billion in 2025, growing at a compound annual growth rate (CAGR) of 18.6%.
The previous period's growth is primarily due to advancements in regenerative medicine, the rising occurrence of chronic diseases, improved comprehension of cellular biology, and patients' inclination towards personalized medicine. Additionally, clinical accomplishments and favorable outcomes also contributed to the growth.
How Does the Forecast Look for the Autologous Cell Therapy Market?
The autologous cell therapy market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for autologous cell therapy is anticipated to experience a significant expansion in the upcoming years, eventually reaching a substantial size of $23.33 billion in 2029, with a compound annual growth rate (CAGR) of 17.6%.
This prospective escalation during the forecast period is linked to the sustained growth in regenerative medicine, broadening utilization across diverse medical disciplines, progression in cell culture methods, escalated investment and research endeavors, regulatory backing, and standardization. Foreseen trends for the forecast period encompass the evolution of automated manufacturing technologies, the inclusion of biomarkers in treatment methodologies, the rise of point-of-care cell processing, an extension beyond hematopoietic stem cells, and industry collaboration and partnership strategies.
What Main Forces Are Fueling Expansion In The Autologous Cell Therapy Market?
The anticipated surge in autologous cell therapy is largely contributed by the high incidence of chronic illnesses. Chronic diseases are ailments that persist for a length exceeding one year and necessitate continuous medical intervention. Autologous cell therapy presents a hopeful recourse for the treatment and control of such diseases, employing the same individual's cells that are grown and expanded externally before being reinserted into the donor. For example, a prediction by the National Library of Medicine, an agency based in the US, in January 2023 stated that by 2050, the count of individuals in the US who are at least 50 years old and have a minimum of 1 chronic condition would escalate to 142.66 million. Hence, the widespread occurrence of chronic diseases is fuelling the expansion of the autologous cell therapy market.
What Are The Primary Segments In The Global Autologous Cell Therapy Market?
The autologous cell therapy market covered in this report is segmented –
1) By Therapy: Autologous Stem Cell Therapy, Autologous Cellular Immunotherapies
2) By Source: Bone Marrow, Epidermis, Mesenchymal Stem Cells, Hematopoietic Stem Cells, Chondrocytes, Other Sources
3) By Application: Cancer, Neurodegenerative Disorders, Cardiovascular Disorders, Autoimmune Disorders, Orthopedics, Wound Healing, Other Applications
4) By End User: Hospitals And Clinics, Ambulatory Centers, Academics And Research, Other End-Users
Subsegments:
1) By Autologous Stem Cell Therapy: Hematopoietic Stem Cell Transplantation, Mesenchymal Stem Cell Therapy, Adipose-Derived Stem Cell Therapy
2) By Autologous Cellular Immunotherapies: Chimeric Antigen Receptor (CAR) T-Cell Therapy, Tumor-Infiltrating Lymphocyte (TIL) Therapy, Dendritic Cell Therapy
Pre-Book The Autologous Cell Therapy Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Key Trends Are Driving Changes In The Autologous Cell Therapy Market?
The progress of technology plays a pivotal role in driving the autologous cell therapy market's popularity. The sector's leading companies are incorporating automation into the autologous cell therapy procedure to enhance efficiency and maintain their operations. For instance, the pharmaceutical, biotechnology, and nutrition manufacturing company based in Switzerland, Lonza, launched the Cocoon Platform in April 2022. This revolutionary technology is for producing customised cell and gene therapies. Using an automated, closed system, the Cocoon Platform significantly diminishes contamination risks, ensuring the manufacturing process remains sterile. Consequently, it elevates quality, reduces labour and material expenditures, and facilitates successful scaling-up of autologous T-cell products.
Who Are the Key Players in the Autologous Cell Therapy Market?
Major companies operating in the autologous cell therapy market include:
• Bristol-Myers Squibb Company
• Novartis AG
• Vericel Corporation
• Holostem Terapie Avanzate S.r.l.
• Pharmicell Co. Ltd.
• Opexa Therapeutics Inc.
• Tego Science AB
• Brainstorm Cell Therapeutics Inc.
• Caladrius Biosciences Inc.
• Lineage Cell Therapeutics Inc.
• Castle Creek Biosciences Inc.
• Gilead Sciences Inc.
• Johnson & Johnson
• CORESTEM Inc.
• Dendreon Pharmaceuticals LLC
• Medipost Co. Ltd.
• PharmaJet Inc.
• Bioject Medical Technologies Inc.
• Medical International Technology Inc.
• INJEX Pharma AG
• Lonza Group Ltd.
• Corning Incorporated
• Takeda Pharmaceutical Company Limited
• CSL Limited
• AstraZeneca plc
• Moderna Inc.
• Sinovac Biotech Ltd.
• Valneva SE
• Bavarian Nordic A/S
• Dynavax Technologies Corporation
What Is The Most Dominant Region In The Autologous Cell Therapy Market?
North America was the largest region in the autologous cell therapy market in 2024.Asia-pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autologous cell therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
